- Home
- CRVS vs AVK Comparison
CRVS vs AVK Comparison
Compare CRVS & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- AVK
- Stock Information
- Founded
- CRVS 2014
- AVK 2003
- Country
- CRVS United States
- AVK United States
- Employees
- CRVS N/A
- AVK N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- AVK Trusts Except Educational Religious and Charitable
- Sector
- CRVS Health Care
- AVK Finance
- Exchange
- CRVS Nasdaq
- AVK Nasdaq
- Market Cap
- CRVS 459.0M
- AVK 547.4M
- IPO Year
- CRVS 2016
- AVK N/A
- Fundamental
- Price
- CRVS $5.83
- AVK $12.67
- Analyst Decision
- CRVS Strong Buy
- AVK
- Analyst Count
- CRVS 4
- AVK 0
- Target Price
- CRVS $15.00
- AVK N/A
- AVG Volume (30 Days)
- CRVS 596.4K
- AVK 112.9K
- Earning Date
- CRVS 11-11-2025
- AVK 01-01-0001
- Dividend Yield
- CRVS N/A
- AVK 11.85%
- EPS Growth
- CRVS N/A
- AVK N/A
- EPS
- CRVS N/A
- AVK N/A
- Revenue
- CRVS N/A
- AVK N/A
- Revenue This Year
- CRVS N/A
- AVK N/A
- Revenue Next Year
- CRVS N/A
- AVK N/A
- P/E Ratio
- CRVS N/A
- AVK N/A
- Revenue Growth
- CRVS N/A
- AVK N/A
- 52 Week Low
- CRVS $2.54
- AVK $9.24
- 52 Week High
- CRVS $10.00
- AVK $12.16
- Technical
- Relative Strength Index (RSI)
- CRVS 58.56
- AVK 67.90
- Support Level
- CRVS $5.90
- AVK $12.42
- Resistance Level
- CRVS $6.30
- AVK $12.57
- Average True Range (ATR)
- CRVS 0.32
- AVK 0.08
- MACD
- CRVS -0.00
- AVK 0.01
- Stochastic Oscillator
- CRVS 53.92
- AVK 80.24
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.